Nomura Asset Management Co. Ltd. Boosts Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Nomura Asset Management Co. Ltd. lifted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 5.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 91,374 shares of the biopharmaceutical company’s stock after acquiring an additional 4,531 shares during the period. Nomura Asset Management Co. Ltd. owned approximately 0.07% of Alnylam Pharmaceuticals worth $29,796,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Brighton Jones LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth $243,000. Mutual of America Capital Management LLC boosted its position in shares of Alnylam Pharmaceuticals by 673.9% during the first quarter. Mutual of America Capital Management LLC now owns 13,644 shares of the biopharmaceutical company’s stock valued at $3,684,000 after buying an additional 11,881 shares during the last quarter. Larson Financial Group LLC increased its holdings in Alnylam Pharmaceuticals by 77.7% in the 1st quarter. Larson Financial Group LLC now owns 199 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 87 shares in the last quarter. Lindbrook Capital LLC raised its position in Alnylam Pharmaceuticals by 9.2% in the 1st quarter. Lindbrook Capital LLC now owns 596 shares of the biopharmaceutical company’s stock worth $161,000 after buying an additional 50 shares during the last quarter. Finally, Allianz Asset Management GmbH raised its position in Alnylam Pharmaceuticals by 100.7% in the 1st quarter. Allianz Asset Management GmbH now owns 218,503 shares of the biopharmaceutical company’s stock worth $59,000,000 after buying an additional 109,632 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Stock Up 0.4%

ALNY opened at $462.30 on Wednesday. The stock has a market cap of $61.08 billion, a price-to-earnings ratio of -187.17 and a beta of 0.30. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The firm’s fifty day moving average is $458.52 and its 200 day moving average is $387.70. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 15,650 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $453.69, for a total transaction of $7,100,248.50. Following the sale, the chief executive officer owned 65,409 shares of the company’s stock, valued at approximately $29,675,409.21. This trade represents a 19.31% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Pushkal Garg sold 3,022 shares of the business’s stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $451.48, for a total value of $1,364,372.56. Following the completion of the transaction, the executive vice president directly owned 20,221 shares in the company, valued at approximately $9,129,377.08. This represents a 13.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 56,200 shares of company stock valued at $25,709,053. 1.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have recently commented on ALNY. Wells Fargo & Company lifted their price target on shares of Alnylam Pharmaceuticals from $395.00 to $479.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 11th. Barclays increased their price target on shares of Alnylam Pharmaceuticals from $460.00 to $527.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Wolfe Research raised shares of Alnylam Pharmaceuticals from an “underperform” rating to a “peer perform” rating in a research report on Monday, August 4th. HC Wainwright set a $570.00 target price on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, November 4th. Finally, JPMorgan Chase & Co. cut their price target on Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating for the company in a report on Monday, October 13th. Twenty-three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $482.17.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.